학술논문
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
Document Type
Article
Author
Oaknin, Ana; Gladieff, Laurence; Martínez-García, Jerónimo; Villacampa, Guillermo; Takekuma, Munetaka; De Giorgi, Ugo; Lindemann, Kristina; Woelber, Linn; Colombo, Nicoletta; Duska, Linda; Leary, Alexandra; Godoy-Ortiz, Ana; Nishio, Shin; Angelergues, Antoine; Rubio, Maria Jesús; Fariñas-Madrid, Lorena; Yamaguchi, Satoshi; Lorusso, Domenica; Ray-Coquard, Isabelle; Manso, Luis; Joly, Florence; Alarcón, Jesús; Follana, Philippe; Romero, Ignacio; Lebreton, Coriolan; Pérez-Fidalgo, J Alejandro; Yunokawa, Mayu; Dahlstrand, Hanna; D'Hondt, Véronique; Randall, Leslie M; Abadie-Lacourtoisie, Sophie; Andreetta, Claudia; Anzizar, Nerea; Aoki, Daiseuke; Barretina-Ginesta, Maria-Pilar; Battista, Marco; Bellier, Charlotte; Bentzen, Anne Gry; Berton, Dominique; Billemont, Bertrand; Bjørge, Line; Bjurberg, Maria; Black, Destin; Bologna, Alessandra; Braicu, Elena Ioana; Casanova, Claudia; Chekerov, Radoslav; Chevalier, Annick; Cueva, Juan Fernando; Czogalla, Bastian; Delanoy, Nicolas; Denschlag, Dominik; Derke, Oscar; Eichbaum, Michael; Enomoto, Takayuki; Esteban, Carmen; Fabbro, Michel; Fehm, Tanja; Ferrero, Annamaria; Fleisch, Markus; Floquet, Anne; Frassoldati, Antonio; Gaba, Lydia; Gadducci, Angiolo; García, Yolanda; Geuna, Elena; Guerra, Eva; Hanker, Lars; Hardy-Bessard, Anne-Claire; Harter, Philipp; Hasegawa, Kosei; Hellman, Kristina; Herrero, Ana; Hilpert, Felix; Katsaros, Dionyssios; Koegel, Matthias; Koliadi, Anthoula; Kurtz, Jean-Emmanuel; Lampe, Bjoern; Lissoni, Andrea Alberto; Lortholary, Alain; Mangili, Giorgia; Mansi, Laura; Marmé, Frederik; Mathews, Cara; Mina, William; Minobe, Shinichiro; Moxley, Katherine; Nagao, Shoji; Nicoletto, Ornella; Nishino, Koji; Nishio, Hiroshi; Nishio, Shin; Oaknin, Ana; Onstad, Michaela; Pardo, Beatriz; Pérez-Fidalgo, J Alejandro; Pisano, Carmela; Poveda, Andrés; Radosa, Julia; Randall, Leslie M.; Ray-Coquard, Isabelle; Redondo, Andrés; Richardson, Debra; Romero, Ignacio; Ronzino, Graziana; Rubio, Maria Jesús; Selle, Frederic; Takekuma, Munetaka; Takeshima, Nobuhiro; Tasca, Giulia; Tewari, Krishnansu; Todo, Yukiharu; Valabrega, Giorgio; Wimberger, Pauline; Woelber, Linn; Yamaguchi, Satoshi; You, Benoît; Yunokawa, Mayu
Source
The Lancet; January 2024, Vol. 403 Issue: 10421 p31-43, 13p
Subject
Language
ISSN
01406736; 1474547X
Abstract
The GOG240 trial established bevacizumab with chemotherapy as standard first-line therapy for metastatic or recurrent cervical cancer. In the BEATcc trial (ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030), we aimed to evaluate the addition of an immune checkpoint inhibitor to this standard backbone.